Using SMO-inhibitor resistant pancreatic cancer cells we also confirm a previous report showing that DYRK1B targeting in pancreatic cancer cells has pronounced therapeutic efficacy in vitro and in vivo, though the molecular mechanisms including the link to HH/GLI signaling remained unidentified in this study [56]. The gene discussed is SMO; the disease is familial pancreatic carcinoma.